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TSH Is a Negative Regulator of Skeletal Remodeling
bone formation. Hyperthyroid states in both humansEtsuko Abe,1,2 Russell C. Marians,1 Wanqin Yu,1,2
and animals similarly display a temporal uncoupling andXue-Bin Wu,1,2 Takao Ando,1 Yanan Li,3
hence a high remodeling bone loss (Greenspan andJameel Iqbal,1,2 Leslie Eldeiry,1,2
Greenspan, 1999). A different form of uncoupling occursGopalan Rajendren,1,2 Harry C. Blair,3,4
in Paget’s bone disease. Here, bone formation dissoci-Terry F. Davies,1 and Mone Zaidi1,2
ates both temporally and spatially from bone resorption1Mount Sinai Bone Program
and becomes rapid, autonomous, and disorganized.Department of Medicine
This results typically in focal osteosclerosis character-Mount Sinai School of Medicine
ized by disordered collagen deposition and the forma-New York, New York 10029
tion of woven, as opposed to lamellar bone, sometimes2 Veterans Affairs Medical Center
at unresorbed sites.Bronx, New York 10463
Physiologic mechanisms controlling skeletal remodel-3 Department of Pathology
ing have unraveled only recently through the applicationUniversity of Pittsburgh
of genetic manipulation. It is clear that molecules thatPittsburgh, Pennsylvania 15213
are necessary for either bone formation or bone resorp-4 Veterans Affairs Medical Center
tion, when deleted, produce an overt skeletal pheno-Pittsburgh, PA 15213
type. Thus, osteoblast formation is abrogated in Runx-2-
or osterix-deficient mice (Karsenty and Wagner, 2002).
Likewise, profound osteopetrosis due to absent osteo-Summary
clast formation ensues when M-CSF, c-fos or RANK-L
are absent (for review, see Zaidi et al., 2003). In contrast,The established function of thyroid stimulating hor-
seemingly important resorption activators, such as in-mone (TSH) is to promote thyroid follicle development
terleukin-6 and tumor necrosis factor- that markedlyand hormone secretion. The osteoporosis associated
affect bone cells in vitro, when deleted in mice, do notwith hyperthyroidism is traditionally viewed as a sec-
produce osteopetrosis. Similarly, not many osteoclastondary consequence of altered thyroid function. We
inhibitors cause an accelerated resorption when de-provide evidence for direct effects of TSH on both
leted, likely because of degenerate mechanisms de-components of skeletal remodeling, osteoblastic bone
signed to prevent excessive skeletal loss. Even the dele-formation, and osteoclastic bone resorption, mediated
tion of both estrogen receptors  and , together,via the TSH receptor (TSHR) found on osteoblast and
produces not as pronounced a phenotype as would beosteoclast precursors. Even a 50% reduction in TSHR
expected from estrogen’s in vitro action (Sims et al.,expression produces profound osteoporosis (bone
2003). Thus, for its deficiency to result in profound boneloss) together with focal osteosclerosis (localized
loss, a given molecule must not only be necessary forbone formation). TSH inhibits osteoclast formation
skeletal maintenance, but must also overcome compen-and survival by attenuating JNK/c-jun and NFB sig-
sation and redundancy (Zaidi et al., 2003).naling triggered in response to RANK-L and TNF.
The only established biologic function of thyroid stim-TSH also inhibits osteoblast differentiation and type 1
ulating hormone (TSH) is to regulate the synthesis andcollagen expression in a Runx-2- and osterix-indepen-
secretion of thyroid hormone from thyroid follicular cells.dent manner by downregulating Wnt (LRP-5) and VEGF
Here, it interacts with a seven transmembrane, glycosy-(Flk) signaling. These studies define a role for TSH as
lated G protein-coupled TSH receptor (TSHR). It hasa single molecular switch in the independent control
been shown through binding studies and immunodetec-
of both bone formation and resorption.
tion that cells and organs other than the thyroid, includ-
ing lymphocytes, the pituitary, thymus, testes, kidney,
Introduction brain, adipose tissue, and fibroblasts express TSHRs
(for review, see Davies et al., 2002). Several biological
Mammalian skeletal remodeling occurs throughout life roles for TSH have thus been speculated. For example,
whereby old bone that is resorbed by the osteoclast is TSH is thought to play a role in recruiting intestinal epi-
replaced by new bone deposited by the osteoblast (Blair thelial lymphocyte subsets to the gut (Wang and Klein,
et al., 2002). The processes of resorption and formation 1995). TSHRs on preadipocytes are thought to induce
are coupled tightly in a temporal and spatial sequence lipolysis and a thermogenic response (Valyasevi et al.,
ensuring the maintenance of skeletal mass and integrity 1999). Likewise, TSHRs in anterior pituitary folliculo-stel-
(Karsenty and Wagner, 2002). Osteoporosis, a major late cells have been implicated as ultra short loop regula-
public health hazard worldwide, results from the loss of tors of TSH production itself (Kohn et al., 1995). And,
such temporal coupling (Manolagas and Jilka, 1995). finally, in astrocytes throughout the brain, as well as in
Postmenopausal hypogonadism, a major cause of hu- neurons of the hypothalamus, hippocampus, and pyri-
man osteoporosis, arises from osteoclastic activation form and postcingulate cortices, TSH may regulate the
triggering an increased resorption rate that is not fully hypothalamic-pituitary axis (Prummel et al., 2000). For
compensated even by an accompanying increase in none of these actions, however, has TSH been shown
to be either necessary or sufficient.
TSH has never been shown to have physiologically*Correspondence: mone.zaidi@mssm.edu
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relevant effects on bone or bone cells. The osteoporosis gotes with normal circulating T4 and T3 levels showed a
significant BMD reduction (p  0.01). Thyroid extractof human hyperthyroidism that is associated with low
or undetectable TSH levels has traditionally been attrib- supplementation to TSHR null mice did not normalize
the BMD change (Figure 1A) confirming that the boneuted instead to elevated thyroid hormone (T3 and T4)
levels. Likewise, the high bone mass accompanying the loss was independent of T3 and T4 levels. Histomorpho-
metry revealed significant increases in TRAP-labeledelevated TSH in hypothyroidism is thought to result from
low thyroid hormone levels. There is indeed a substan- surfaces in vertebral bodies of TSHR/ mice, sugges-
tive of increased osteoclastic bone resorption (Table 2).tive body of early literature on the effects of thyroid
hormones on bone remodeling, both resorption and for- Finally, calvarial thickness was reduced significantly in
the supplemented TSHR/ mice compared with wild-mation, in vitro (Bordier et al., 1967; Sato et al., 1987;
Britto et al., 1994). Nonetheless, remodeling is not un- type littermates (p  0.01) (Figure 1B).
In addition to the systemic bone loss despite normalcoupled in mice lacking the 1 and  thyroid hormone
receptors (TRs). These mice instead display skeletal calcium, TSH and T3/T4, there was increased bone turn-
over with increased woven bone in both heterozygotesmorphogenesis and growth plate abnormalities (Gothe
et al., 1999). That 1/ TR deficiency essentially pro- and null mice. In thyroid-replaced, TSHR-deficient mice
this increase in bone turnover was dramatic. High turn-duces no remodeling phenotype prompted us to specu-
late that the osteoporosis and the increased bone mass over states typically show variability in BMD, and, de-
spite overall decreases in BMD (Figure 1A), irregularseen, respectively, in hyper- and hypothyroidism could
potentially arise from altered TSH levels. cortical thickening occurred in idiosyncratic locations in
long bones (Figure 1C). Histology of vertebral cancellousThus, we attempted, in this study, to examine for di-
rect, hitherto unknown effects of TSH on bone remodel- bone showed disorganized trabeculae resembling Pag-
etic bone (Figure 1D) with significant increases in meaning using complementary cellular and molecular ap-
proaches, notably through the use of TSHR null mice. trabecular width in TSHR/mice (Table 2). Woven bone,
the characteristic of rapid bone formation, was seen byWe demonstrate that even a 50% reduction in TSHRs
in euthyroid mice results in pronounced osteoporosis polarization microscopy to be increased in all areas. In
recently formed cortical bone, it was often difficult toand focal osteosclerosis, that TSHRs are abundant on
both osteoclast and osteoblast precursors and that TSH detect lamellar bone in null mice, where control bone
was entirely lamellar (Figure 1E, lower images). In keep-negatively regulates both osteoclastic bone resorption
and osteoblastic bone formation by attenuating distinct ing with these observations, calcein double-labeling
studies in TSHR/ mice showed that mineralizing sur-signals. The data thus implicate TSH as a single neces-
sary molecular switch that negatively regulates both faces increased 50% with normal interlabel distances
(Table 2).components of skeletal remodeling.
To examine the cellular basis of the osteoporosis and
focal sclerosis, we compared both osteoclast and os-Results
teoblast formation ex vivo in bone marrow cultures (see
Experimental Procedures). Osteoclast formation was in-TSHR Knockout Mice Display High Turnover
creased by2-fold in cultures from TSHR/ and TSHR/Osteoporosis and Focal Osteosclerosis
mice compared to wild-type cultures (Figures 2A–2D).Our group generated TSHR null mice by deleting exon
This was associated with a marked increase in expres-1 of the mouse TSHR gene through homologous recom-
sion of the osteoclast markers TRAP and the calcitoninbination in embryonic stem cells and replacing it with a
receptor (Figure 2E). Likewise, colony forming unit-fibro-GFP cassette (Marians et al., 2002). GFP expression,
blast (CFU-F) and colony forming unit-osteoblast (CFU-in lieu of gene deletion, allowed us to examine TSHR
OB) counts were increased in stromal cell cultures fromlocalization in situ. Intense GFP fluorescence was de-
TSH/ and TSH/ mice compared with wild-type cul-tected in thyroid follicles of TSHR/ and TSHR/ mice.
tures (Figure 2F–2M). The increase in osteoblast differ-Thyroid follicles were poorly developed in TSHR/
entiation in TSHR null and heterozygote mice was asso-mice, not unexpectedly, as follicular growth and differ-
ciated with enhanced expression of type 1 collagen,entiation are TSH-dependent. Western blots of thyroid
bone sialoprotein (BSP), and osteocalcin both in CFU-Fhomogenates showed an expected 50% decrease of
colonies and long bone extracts (Figures 2N and 2O).TSHR expression in the heterozygotes and an absent
That a prominent cellular phenotype was evident despiteexpression in TSHR null mice.
only a 50% reduction in the TSHR content suggests anTSHR null mice were runted, hypothyroid, and died
important skeletal effect of TSH.by 10 weeks of age. Body weight and femur length and
weight were all reduced (Table 1). Serum T3 and T4 levels
were undetectable and TSH levels were elevated several Bone Cell Precursors Express TSHRs
High-resolution dual photon confocal imaging showedthousand-fold. In contrast, the heterozygotes thrived
and reproduced normally with normal serum T4, T3, and GFP fluorescence in cells that resembled osteoblast and
osteoclast precursors in the inner skull table (Figure 3A).TSH levels (Table 1). Dietary supplementation of TSHR/
mice with thyroid extract (100 ppm) at weaning normal- Intense GFP fluorescence was also observed ex vivo
in CFU-Fs at day 10 and in mononucleated osteoclastized body weight, but not bone weight or bone length
(except femur weight) (Table 1). Serum calcium levels precursors at day 6 (Figure 3B). Quantitative FACS anal-
ysis showed a dramatic increase in GFP-expressing cellswere normal in all groups.
TSHR null mice had severe osteoporosis at all sites following RANK-L and M-CSF exposure (Figure 3C). The
temporal sequence of TSHR expression, examined byas assessed by Piximus-based bone mineral density
(BMD) measurements (Figure 1A). Even the heterozy- immunostaining, coincided with calcitonin receptor ex-
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Table 1. Phenotypic Features of the TSHR Null Mouse
/ / / /(TH)
Body weight (g) 20.1  1.2 23.6  0.5 14.1  1.1* 22.8  0.9
Femur length (cm) 1.40  0.04 1.38  0.03 1.25  0.03* 1.18  0.03
Femur weight (mg) 76.0  4.0 79.0  6.0 62.0  6.0* 72.0  6.0
T4 (mg/dl) 4.0  0.6 6.8  0.8 ND 4.2  0.7
T3 (ng/dl) 80.4  4.0 78.8  3.8 ND 93.0  5.0
TSH (mU/ml) 61.5  7.4 83.8  8.8 31,000* 75.4  3.8
Calcium (mg/dl) 9.7  0.3 9.7  0.5 NT 9.8  0.3
The results are shown as means  standard error of the means. Statistics: analysis of variance for each variable comparing heterozygote
(/) or null (/) mice with or without thyroid extract (TH) supplementation to wild type (/) littermates. *p  0.01. ND: not detectable.
NT: not tested.
pression (day 2), but preceded TRAP expression (day TSHRs (Ando et al., 2002), specifically bound 125I-TSH
(Figure 3G). Limited expression of TSHR was also noted3) (Figure 3D).
RT-PCR on mRNA isolated from osteoclast precursor in UAMS-33 preosteoblasts (Lecka-Czernik et al., 1999)
using both RT-PCR and FACS (data not shown). To-and CFU-F colonies displayed expected bands in wild-
type mice, but not in TSHR null mice (Figure 3E). TSHR gether, these findings indicate that TSHR expression is
maximal during the early and mid phases of osteoclastprotein expression was confirmed in the same cultures
by FACS using a murine monoclonal antibody RSR-1 and osteoblast formation.
raised to the human TSHR (epitope: amino acids 381–
385,  subunit, kindly provided by Dr. Smith, FIRS Labo- TSH Regulates Osteoclast Formation,
Function, and Fateratories, Cardiff, UK) (Figure 3F). Finally, the osteoclast
precursor cell line, RAW-C3, as well as, for comparison, Ficoll-purified hematopoetic stem cells were cultured
for 6 days with RANK-L and M-CSF in the presenceCHO-cells transfected with either human or murine
Figure 1. Osteoporosis and Focal Sclerosis in the TSH Receptor (TSHR) Knockout Mouse
(A) Reduced bone mineral density (BMD) in TSHR/ and TSHR/ mice. A Piximus (Lunar) small animal bone densitometer was used to
measure bone mineral density (BMD) at the indicated sites. Of note is that supplement of dietary thyroid tissue extract (TH), rendering TSHR/
mice euthyroid (Table 1), failed to reverse the osteoporotic phenotype.
(B) Calvarial area (cm2) and thickness (m) at parietal plate in the mid region, measured through digital image analysis. Statistics for (A) and
(B): comparisons with wild-type littermates by analysis of variance; *p  0.01.
(C) Microradiographs of TSHR/ and TSHR/ mice indicating areas of focal radioopacities (arrow).
(D) Hematoxylin-eosin staining of corresponding vertebral bodies from TSHR/ and TSHR/ mice and wild-type littermates, indicating focal
sclerotic areas by arrows (magnification  20).
(E) Hematoxylin-eosin staining (upper images) and corresponding polarized micrographs (lower images) showing the disorganized collagen
orientation (woven bone) in TSHR/ mice compared with normal lamellar collagen orientation in wild-type littermates.
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Table 2. Bone Histomorphometry of the TSHR Null Mouse
Bone and Parameter (units) / / /
[Abbreviation]
Tibia, Diaphysis
Cortex (m) 112  6 103  7 98 10
[Ct.Wi]
Vertebra, L3
TRAP labeled surface (%) 20.9  3.0 22.3  2.9 31.1  3.8*
[OC.S]
Trabecular width (m) 23.1  1.7 26.8  1.5* 27.9  1.6*
[Tb.W]
Mineralizing surface (%) 18.7  4.7 22.7  12.4 30.2  7.0*
[(dLS  sLS/2)/BS]
Interlabel distance (m) 21  3 22  3 23  4
[Ir.L.Th]
Bone area (mm2) 2.0  0.2 1.9  0.2 1.8  0.3
[B.Ar]
Trabecular Bone Area 25.7  2.0 23.8  1.08 19.1  1.4*
(TBA 	 BA/TA)
Histological measurements and calculated parameters in cortex and cancellous bone of 6-week-old, calcein-labeled, wild type (/), heterozy-
gotic (/), and null (/) mice. Mineralizing surface is corrected for total surface; other measurements are from trichrome or von Kossa
stained undecalcified or hematoxylin and eosin decalcified stained sections by digital measurements of photomicrographs as described.
Nonstandard units are as defined by Parfitt et al., 1987. In vivo and ex vivo osteoclast labeling used the method of Webber et al., 1988.
Mean  standard deviations for cross sections from six animals per group. *Different from wild type p  0.05.
of recombinant human TSH (rhTSH). rhTSH caused a with an inhibition of the RANK-L-induced stimulation of
osteoclast markers, namely TRAP, cathepsin K, calcito-concentration-dependent inhibition of osteoclast forma-
tion (Figure 4A). RAW-C3 cells were cultured in parallel nin receptor, and 3 integrin measured by real-time PCR
(Figure 4C).with RANK-L for 6 days with or without rhTSH (10 U/l).
TSH inhibited the osteoclastogenic effect at every We next compared resorption of dentin slices by os-
teoclasts derived from TSHR/, TSHR/, and TSHR/RANK-L concentration (Figure 4B). This was associated
Figure 2. Effect of TSHR Deletion on Osteoblast and Osteoclast Formation in Bone Marrow Cell Cultures
Bone marrow cells were isolated from 6-week-old TSHR/, TSHR/, and TSHR/ mice. Ficoll-separated hematopoetic stem cells were
cultured with RANK-L (60 ng/ml) and M-CSF (30 ng/ml) allowing for the formation of TRAP-positive osteoclasts (A–D). TRAP and calcitonin
receptor (CTR) mRNA expression (fold increase) was quantitated by real-time PCR (E). The stromal cell fraction was allowed to differentiate
in ascorbic acid-2-phosphate (1 mM) to form alkaline phosphatase-positive fibroblastoid colonies, CFU-Fs, at day 10 (F–I), and mineralized
von Kossa-positive colonies, CFU-OBs, around 21 days (J–M). Bone sialoprotein (BSP), type I collagen (coll), and osteocalcin (OG2) mRNA
expression was quantitated by real-time PCR in CFU-Fs (Figure 2N) and long bones (Figure 2O), and is expressed as a fold increase (wild-
type). Statistics by analysis of variance compared with the wild-type littermates, *p  0.01.
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Figure 3. Expression of the TSHR in Bone Cells
(A) Dual photon confocal micrographs of calvaria from TSHR/ mice showing GFP fluorescence from an osteoclast precursor (oc) and an
osteoblast precursor (ob).
(B) Upper image: GFP expression in mononuclear osteoclast precursors (oc) following 6 day culture of Ficoll-purified hematopoetic stem cells
from TSHR/ and TSHR/ mice with M-CSF (30 ng/ml) and RANK-L (60 ng/ml). No intense GFP fluorescence in control (TSHR/) cultures.
Lower image: GFP expression in colony forming units-fibroblasts (CFU-F) colonies formed after a 10 day incubation of bone marrow stromal
cell cultures from TSHR/ and TSHR/ mice in differentiating conditions (1 mM ascorbic acid-2-phosphate).
(C) FACS quantitation of GFP fluorescence in hematopoietic stem cell cultures incubated with RANK-L and/or M-CSF, as above. MFI-mean
fluorescence intensity of GFP-negative (open column) and GFP-positive (filled column) cells.
(D) Immunodetection of TSHR, RANK, and calcitonin receptors (CTR) and tartrate-resistant acid phosphatase (TRAP) staining during osteo-
clastogenesis in bone marrow cell cultures from wild-type mice (see Experimental Procedures for details).
(E) RT-PCR evidence for TSHR expression in osteoclast precursors (oc) and osteoblast precursors (CFU-Fs), cultured as described above,
from wild-type and TSHR/ mice. Lane M: markers. Arrow: 203 bp.
(F) TSHR protein expression in osteoclast precursors (oc) and CFU-F colonies from wild-type mice analyzed by FACS. Percent cells in the
M1 and M2 zones are indicated. Black: no added antibody; red: goat antimouse IgG (0.4 g/ml); green: mouse antihuman TSHR (RSR-1)
antibody (10g/ml) followed by goat antimouse IgG (0.4g/ml). Note the spectral shift of the green zone toward M2 indicating protein expression.
(G) Specific 125I-TSH binding to intact CHO cells, CHO cells transfected with murine (m) or human (h) TSHR, and RAW-C3 (C3) cells. Cells
were incubated with 10,000 cpm of 125I-bTSH in the absence or presence of cold bTSH (106 mU/l), and radioactivity in the cell lysates was
counted. The binding of the 125I-bTSH was expressed as a % bound in each cell line. The values are average of the quadruplicate samples.
following a 6 day incubation with RANK-L and M-CSF tact cell membranes (Figure 5B). Cell number in infected
cells was reduced by 15% (p  0.05). In separatein the presence or absence of rhTSH (10 U/l). Resorption,
quantitated as the number of pits per slice, was in- experiments, TSH stimulated apoptosis in mature osteo-
clasts derived from RAW-C3 cells (Vincent et al., 2001)creased significantly in TSHR/ cultures compared with
wild-type cultures (Figure 4D). Expectedly, TSH inhibited in a concentration-dependent manner, maximally by
50% (Figure 5C). Together, the results suggest thatresorption by wild-type, but not of TSHR/ osteoclasts
(Figure 4D). TSHR activation by TSH results in attenuated osteoclast
formation, resorption, and survival.Finally, we investigated whether TSH attenuated the
lifespan of osteoclast precursors and mature osteo-
clasts. Otherwise TSHR-negative RAW264.7 cells were TSHR Attenuates Osteoclastogenesis by
Inhibiting JNK/c-jun and NFB Signalinginfected with a retroviral vector containing the hTSHR
gene and protein expression was confirmed by FACS It was necessary to differentiate whether the increased
osteoclastogenesis in TSHR knockout mice arose from(Figure 5A). TSHR-infected cells became annexin V-pos-
itive when treated with TSH, whereas those infected activated osteoclast precursors or whether it was sec-
ondary to enhanced RANK-L or M-CSF production fromwith vector alone, or those not exposed to TSH did not
(Figure 5B). All groups of cells showed similar (minimal) the osteoblast. Basal and 1,25-dihydroxyvitamin D3-
stimulated RANK-L or M-CSF expression in culturedlevels of propidium iodide uptake, indicating largely in-
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Figure 4. TSH Effects on Osteoclast For-
mation
(A) Inhibitory effect of recombinant human (rh)
TSH on the formation of TRAP-positive osteo-
clasts. Hematopoetic stem cells were cul-
tured with RANK-L (60 ng/ml) and M-CSF (30
ng/ml) allowing for osteoclast formation. Sta-
tistics: analysis of variance, *p  0.01, com-
parison of each concentration with zero con-
centration.
(B) Effect of rhTSH (10 U/l) on osteoclast for-
mation from TSHR-positive RAW-C3 cells in-
cubated with various concentrations of
RANK-L. Statistics: Analysis of Variance, p 
0.01 – RANK-L alone versus RANK-LrhTSH.
(C) Expression of osteoclast markers, notably
TRAP, cathepsin K, calcitonin receptor (CTR),
and 3 integrin in response to RANK-L stimu-
lation with or without rhTSH (10 U/l). Statis-
tics: analysis of variance, *p  0.01–vehicle
(Veh) versus treatment; ∧p  0.01 RANK-L
alone versus RANK-LrhTSH.
(D) Effect of rhTSH (10 U/l) or vehicle (Veh) on resorption (pits per slice) by osteoclasts generated from bone marrow derived from TSHR/,
TSH/, and wild-type littermates (per Takahashi et al., 2003). Statistics: analysis of variance, p 0.01, *comparison with TSHR/ (untreated),
∧control versus rhTSH-treated.
calvarial osteoblasts derived from TSHR null or hetero- pared with those derived from wild-type littermates (Fig-
ure 6D). To examine the downstream mechanism further,zygote mice was not elevated compared with wild-type
littermates (Figure 6A). In fact, basal RANK-L expression we used TSHR-positive RAW-C3 cells. Apart from caus-
ing modest increases in ERK1/2 and p38 phosphoryla-was reduced in TSHR/mice. This indicated that loss of
the TSHR did not elevate osteoclast formation through tion (data not shown), TSH potently inhibited basal and
RANK-L-stimulated JNK and I
B phosphorylation (Fig-increased RANK-L or M-CSF expression.
We found that TNF, but not IL-7 levels in the superna- ures 6E and 6F). It likewise attenuated both basal and
RANK-L-induced c-jun, but not c-fos translocation (Fig-tant of freshly isolated bone marrow cells measured by
ELISA were higher by 3-fold in TSHR/ mice (Figure ure 6G). Finally, TSH inhibited RANK-L-induced nuclear
translocation of p65 (Figure 6G). The latter mechanism,6B). This increase in TNF expression was confirmed
by real-time PCR in cultured bone marrow cells (Figure we believe, constitutes a parallel pathway through which
TSH likely impairs osteoclast formation.6B). We next examined whether the elevated TNF
caused the increased osteoclastogenesis in TSHR/
mice. Excess anti-TNF neutralizing antibody blocked TSH Regulates Osteoblast Differentiation by
Attenuating LRP-5 and Flk-1 Expressionthis increase in osteoclast formation (Figure 6C), provid-
ing compelling evidence for TNF as an osteoclasto- Stromal cells derived from bone marrow were allowed
to differentiate in ascorbic acid-2-phosphate (“differ-genic signal mediating the effects of TSHR deletion.
The interaction of TNF and (or) RANK-L with their entiating conditions”). Within 10 days, adherent fibro-
blastoid colonies, CFU-Fs, formed that later mineralized,receptors results in the binding of TNF receptor associ-
ated factors (TRAFs) to their respective intracellular do- at around 21 days, to form CFU-OBs (Figure 7). TSH
inhibited CFU-F and CFU-OB colony formation in a con-mains and the subsequent activation of Akt, MAP ki-
nases (JNK, ERK, and p38) and NF
B (Khosla, 2001; centration-dependent manner (Figures 7A and 7B).
We used two model systems to study the mechanismTeitelbaum and Ross, 2003). JNK, by phosphorylating
c-jun at the N terminus, causes its nuclear translocation of the inhibitory effects of TSH on osteoblast differentia-
tion. First, primary osteoblasts isolated by collagenasefollowed by the binding of homo- and heterodimeric
complexes between c-jun and c-fos to AP-1 sites on digestion from calvaria of 4-day-old mice were cultured
in differentiating conditions. Second, 1-day-old calvarialgene promoters, including those of cathepsin K and
TRAP (Kawaida et al., 2003). Likewise, the two subunits explants were maintained in culture with 1% agarose
under differentiating conditions (Gong et al., 2001). Inof NF
B, p65 and p50, are osteoclastogenic, and their
nuclear translocation is inhibited by dephosphorylated both systems, TSH (10 U/l) was applied for the entire 6
day culture period. Real-time PCR was employed onI
B. As phosphorylated I
B is degraded through ubi-
quitination, inhibition of such phosphorylation by TSH RNA extracted from cells or calvarial explants to exam-
ine the expression of the osteoblast markers type 1could make more dephosphorylated I
B available for
binding to, and thus decreasing the nuclear transloca- collagen, BSP and osteocalcin, the critical transcription
factors Runx-2 and osterix, and the prodifferentiationtion of the NF
B heterodimers.
Consistent with our premise that upregulated TNF receptors LRP-5 and Flk-1 (Karsenty and Wagner, 2002).
LRP-5, the coreceptor involved in Wnt signaling, pro-signaling underlies the increased osteoclastogenesis in
the TSHR/ mouse, we found that steady-state levels motes osteoblast differentiation and its mutation or de-
letion is associated with severe osteoporosis (Gong etof phosphorylated JNK and I
B were increased in os-
teoclasts derived from TSHR/ and TSHR/ mice com- al., 2001). Likewise, Flk-1, a VEGF receptor, is critical
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Figure 5. TSH Effects on Osteoclast and Osteoclast Precursor Survival
(A) FACS analysis to assess the expression of the TSHR in RAW264.7 cells infected with either empty pLXSN retroviral vector (RAW-Cont) or
vector containing the human TSHR gene (RAW-TSHR). Percent cells in the M1 and M2 zones are indicated. Black: no added antibody; green:
mouse antihuman TSHR (RSR-1) antibody (10 g/ml) followed by goat antimouse IgG (FITC-labeled, 0.4 g/ml). Note the spectral shift of the
green zone toward M2 indicates protein expression.
(B) RAW-TSHR and RAW-Cont cells were treated with rhTSH (10 U/l) or vehicle without FBS for 6 hr. Annexin (annex) V (1 g/ml) and propidium
iodide (PI) (0.2% v/v) were applied together for 10 min, followed by fluorescence microscopy using green (annexin label) and red (PI label)
filters to visualize the two fluorochromes, respectively. Note that RAW-TSHR cells, but not RAW-Cont cells displayed annexin V staining,
indicating increased apoptosis resulting from TSHR activation. Minimal PI staining, indicating a generally intact cell membrane was seen with
both RAW-TSHR and RAW-Cont cells.
(C) Inhibitory effect of rhTSH on the survival of mature TRAP-positive osteoclasts (oc) formed from TSHR-positive RAW-C3 cells in the presence
of RANK-L (100 ng/ml). Statistics by analysis of variance; *p  0.01, compared with zero concentration.
for endochondral ossification and synergizes the bone dence for a biological role plausible. It has been sug-
gested that TSH plays a role in recruiting specific intesti-formation induced by BMP-4 (Zelzer et al., 2002; Peng
nal epithelial (IE) lymphocyte subsets bearing TSHRs toet al., 2002).
the gut in response to TRH (Wang and Klein, 1995).TSH significantly inhibited type 1 collagen expression,
Functional TSHRs have been demonstrated in dendriticas well as BSP and osteocalcin expression, respectively,
cells and the thymus, wherein, quite curiously, the enzy-in primary calvarial osteoblast (POB) and calvarial ex-
matic apparatus for thyroid hormone synthesis is alsoplant cultures (Figure 7C). Quite surprisingly, Runx-2 and
present (Bagriacik and Klein, 2000). Secondly, there isosterix expression were not significantly suppressed by
evidence that TSH induces lipolysis and could thus beTSH (Figure 7D). Importantly, however, TSH profoundly
thermogenic (Endo et al., 1995). Preadipocytes, whichinhibited LRP-5 and Flk-1 expression (Figure 7E). In par-
arise from the same pluripotent lineage as the osteo-allel, the expression of both LRP-5 and Flk-1 was upreg-
blast, express TSHRs (Valyasevi et al., 1999). Two TSHRulated in TSHR/ long bones compared with wild-type
isoforms have been cloned from a rat adipose tissuebones (Figure 7F). Together, the data provides compel-
cDNA library. The larger isoform is not detected in thy-ling evidence that TSH inhibits osteoblast differentiation
roid tissue, does not bind TSH, and fails to elicit a cAMPthrough a Runx-2- and osterix-independent mechanism
response (Endo et al., 1995). Thus, despite renewedinvolving the downregulation of the prodifferentiation
interest in TSH receptor physiology, none of the sugges-factors, LRP-5 and Flk-1.
tions for a putative role for the receptor have been tested
rigorously using gain-of-function or loss-of-function
Discussion strategies.
Our results show that TSHRs are of fundamental im-
No effects of TSH or the TSHR on bone or bone cells portance in skeletal conservation in adult life. This is
have ever been speculated, except for one report show- evident from a full-blown “high remodeling” skeletal phe-
ing that TSH binds osteogenic sarcoma (UMR106) cell notype seen even when receptor levels are reduced by
membranes (Inoue et al., 1998). It has been surmised, 50% and in the face of unimpaired thyroid function. That
however, that other cells and organs including bone the remodeling defect in euthyroid heterozygotic and
marrow cells, lymphocytes, the pituitary, thymus, testes, hypothyroid null mice is virtually indistinguishable fur-
kidney, brain, adipose tissue, and fibroblasts bear func- ther suggests that TSH action on bone is direct, as
tional TSHRs (for review, see Davies et al., 2002; Wang opposed to being secondary to reduced thyroid hor-
mone levels. Thus, dietary thyroid extract supplementa-et al., 2003). However, only in two instances is the evi-
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Figure 6. Mechanism of the Antiosteoclastogenic Action of TSH
(A) Real-time PCR measurements of RANK-L and M-CSF mRNA expression (fold increase) in primary osteoblasts cultured from TSHR/,
TSHR/, and TSHR/ calvaria that were incubated for 2 days in -MEM without (Veh) or with 1,25-dihydroxyvitamin D3 (108 M). Statistics
comparing null and heterozygote with wild-type vehicle-treated cells, by analysis of variance, *p  0.01.
(B) ELISA measurement of tumor necrosis factor  (TNF) and interleukin-7 (IL-7) in the supernatant (sup) of marrow cells freshly isolated
from TSHR/ (/) and TSHR/ (/) long bones (left image). Real-time PCR measurements for TNF mRNA expression (fold increase) in
osteoclasts derived from TSHR/ (/) and TSHR/ (/) bone marrow cultures (day 4) (right image). Unpaired Student’s t test comparison
with TSHR/ bone marrow supernatants and cultured cells, respectively, p  0.01 (n 	 4 for both experiments).
(C) Effect of a neutralizing antibody to TNF (Ab) on TRAP positive osteoclast (oc) formation following a 4 day culture (see Experimental
Procedures). Comparison with TSHR/ in the presence of goat antimouse IgG, p  0.01.
(D) Western immunoblots showing elevated steady state levels of p-JNK and p-I
B in osteoclasts derived from TSHR/, TSHR/ and
TSHR/ mouse bone marrow cell cultures (day 4).
(E–G) Western immunoblots on lysates prepared from RAW-C3 cells exposed to RANK-L (100 ng/ml), recombinant human (rh) TSH (10 U/l),
or RANK-L (100 ng/ml) plus rhTSH (10 U/l). Phosphorylated (p) JNK (E) and p-I
B (F) was measured in whole-cell lysates. Levels of c-jun,
c-fos, and the NF
B subunits, p65 and p50, were measured in nuclear subfractions (G). Note that rhTSH inhibited basal and RANK-L stimulated
JNK and I
B phosphorylation, as well as the nuclear translocation of c-jun and p65, but not of c-fos and p50.
tion to normalize serum thyroid hormone levels failed osteoporosis suggests that osteoblastic activity, as in
Pagetic bone, is pronounced, autonomous, and, at leastto reverse the low BMD, calvarial thinning, or focal scle-
rosis. in part, dissociated spatially from resorption. Thus, bone
formation appears to occur “ectopically” at sites thatIt is interesting that TSHRs appear to modulate resorp-
tion and formation independently, a phenomenon that have not been previously resorbed, resulting in a focal
sclerotic phenotype accompanying global osteopenia.is undocumented for any other molecule. Normally, ele-
vated osteoclastic resorption, for example, after go- This is consistent with our demonstration that (1) the in
vitro effects of TSH are exerted separately on osteoblastnadal steroid withdrawal, precedes and exceeds the
enhanced bone formation with the primary cellular de- and osteoclast precursors; (2) TSHRs are present on
both cell types; and (3) the osteoclastic phenotype doesfect in ovariectomized mice being increased osteo-
clastogenesis (Riggs et al., 2002). However, due to the not result from enhanced RANK-L and M-CSF expres-
sion in osteoblasts.tight coupling between resorption and formation, bone
formation also increases, but lags behind resorption. TSH thus inhibits osteoclastogenesis and osteoblasto-
genesis through distinct and unrelated mechanisms. ItThe overall result of such high remodeling is osteoporo-
sis, but without focal sclerosis. Formation and resorp- acts on TSHR-bearing osteoclast precursors to inhibit
JNK phosphorylation and the subsequent nuclear trans-tion are not only coupled temporally, but also spatially,
so that each resorptive cavity must be refilled with new location of the transcription factor c-jun. Although we
have not tested this directly, reduced c-jun levels, evenbone to maintain skeletal integrity. That TSHR knockout
mice have focal sclerosis in addition to high remodeling in the face of unaltered c-fos levels, will result in reduced
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Figure 7. TSH Effects on Osteoblast For-
mation
Inhibitory effect of recombinant human (rh)
TSH on the formation of colony forming unit-
fibroblasts (CFU-F) (A) and CFU-osteoblasts
(CFU-OB) (B). Stromal cells were allowed to
differentiate in ascorbic acid-2-phosphate (1
mM). Within 10 days, adherent fibroblastoid
colonies, CFU-Fs, formed that stained posi-
tive for alkaline phosphatase. These colonies,
upon further incubation, mineralized around
21 days to form CFU-OBs that were identifi-
able upon brownish black von Kossa staining.
Statistics by analysis of variance, comparison
with zero dose of rhTSH, p  0.01.
(C–E) Expression levels (test/control), deter-
mined by real-time PCR of type 1 collagen
(coll), bone sialoprotein (BSP), osteocalcin
(OG2) (C), Runx-2 and osterix (D), as well as
LRP-5 and Flk-1 (E) in either primary calvarial
osteoblasts (POB) or primary calvarial explant
cultures (Explant) in response to rhTSH (10
U/l) or vehicle (Veh).
(F) Elevated expression, determined by real-
time PCR (as above), of LRP-5 and Flk-1 in
long bones of TSHR/ and TSH/ compared
with wild-type littermates. Statistics by analy-
sis of variance, *p  0.01, comparing either
to zero concentration (A–E) or to wild-type
cells (F).
homo- and heterodimer formation, and hence, diminish explant cultures. Likewise, receptor expression was
upregulated in TSH/ mice that had enhanced bonethe transcription of critical osteoclast target genes bear-
ing AP-1 sites, such as TRAP and cathepsin K (Kawaida formation and focal sclerosis. Mutations of the LRP-5
gene in humans or its targeted disruption in the mouseet al., 2003). An identical mechanism transduces the
antiosteoclastogenic effect of estrogen (Shevde et al., result in osteopenia; in the latter case, Runx-2 expres-
sion remains normal (Kato et al., 2002). Thus, our result2000; Srivastava et al., 2001). In contrast to estrogen,
however, TSH additionally inhibits I
B phosphoryla- that TSH exerts an effect by inhibiting LRP-5 indepen-
dently of Runx-2 comes as no surprise. We are, however,tion. This makes more dephosphorylated I
B available
to bind to and hence prevent the nuclear translocation less clear on the mechanism through which Flk-1 medi-
ates TSH effects on osteoblastogenesis, except thatof NF
B heterodimers. Interestingly, we found that the
translocation of p65 (and not of p50) was inhibited selec- there is evidence that VEGF can, through Flk-1 activa-
tion, synergize the actions of BMP-4 (Peng et al., 2002).tively in response to TSH. NF
B, the absence of which
results in osteopetrosis without osteoclasts (Iotsova et The latter effect likely occurs through the enhancement
of mesenchymal cell proliferation.al., 1997), regulates the transcription of a variety of genes
during osteoclastogenesis, including ICAM, TLR2, and Finally, it is tempting to speculate that the skeletal
loss that occurs in hyperthyroidism is due to low TSHI
B itself (Wei et al., 2001). It is highly likely therefore
that the two mechanisms, JNK/c-jun and NF
B, acting levels as opposed solely to high T3 and T4 levels. If so,
this would mean revisiting the mechanism of bone lossin concert are responsible for the profound inhibitory
effects of TSH on osteoclast formation. in thyroid disease, particularly in patients on thyroxine
therapy. On one hand, there is substantive early litera-The physiological relevance of both mechanisms was
confirmed ex vivo by the marked enhancement of JNK ture on direct stimulatory effects of thyroid hormone on
osteoblasts and osteoclasts (Bordier et al., 1967; Satoand I
B phosphorylation seen in cells derived from
TSH/ and TSH/ mice. JNK and I
B are both phos- et al., 1987; Britto et al., 1994). On the other hand, mice
rendered null for the1 and thyroid hormone receptorsphorylated in response to TNF that regulates osteo-
clast formation (Lam et al., 2000). Our finding that the (TRs) do not exhibit any bone remodeling defects (Gothe
et al., 1999). TR1// mice instead have abnormali-expression of TNF is enhanced dramatically in vivo
and that a neutralizing anti-TNF antibody inhibits the ties in skeletal maturation characterized by severe runt-
ing and growth plate defects. These features are recapit-enhanced osteoclastogenesis ex vivo in TSHR/ bone
marrow cell cultures suggests TNF as a proosteoclas- ulated only in hypothyroid TSHR/ mice, not in euthyroid
TSHR/ mice that have a profound remodeling pheno-tic signal mediating the effects of TSHR deletion.
The effect of TSH in negatively regulating osteoblast type. Moreover, only the maturation defect and not the
remodeling defect in TSHR/ mice is reversed by thy-formation is independent of both Runx-2 and osterix. We
found that the expression of LRP-5, the Wnt coreceptor, roid replacement. The studies thus make a compelling
argument for the regulation of bone remodeling by TSHand Flk-1, a VEGF receptor, were reduced dramatically
in response to TSH both in primary osteoblasts and and the TSHR, and of skeletal morphogenesis by thyroid
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and osteoblast precursors by conventional epifluorescence micros-hormones. With the recent discovery of RANK-L and
copy complemented by dual photon confocal imaging or immunode-osteoprotegerin expression in thyroid follicles (Hofbauer
tection. In addition, FACS was used to (1) demonstrate TSHR inet al., 2002), it becomes tempting to speculate that the
wild-type osteoblast and osteoclast precursors, including TSHR-
thyroid gland might regulate skeletal morphogenesis positive RAW-C3 cells, and (2) to check for TSHR expression in
and remodeling in unusual ways that require further in- RAW264.7 cells that had been infected with a retrovirus containing
the human TSHR gene (RAW-TSHR) or with empty vector (RAW-vestigation.
control). A mouse monoclonal antihuman TSHR antibody, RSR-1
(epitope: amino acids 381 to 385,  subunit) was employed. CellsExperimental Procedures
were incubated with RSR-1 (10 g/ml, 1 hr) followed by a goat
antimouse IgG (FITC-labeled) (0.4g/ml, 1 hr). For immunodetectionSpecialized Culture Techniques
of TSHR, RANK, and calcitonin receptor during osteoclastogenesis,For the osteoclastogenesis experiments, bone marrow cells were
monoclonal (RSR-1) or polyclonal (antimouse RANK and CTR) anti-isolated from femora and tibiae of mice in -MEM. The cells were
bodies (Santa Cruz Biotechnology Inc., Santa Cruz, CA) were appliedcultured for 2 days with M-CSF (5 ng/ml). Nonadherent cells
to bone marrow cells that had been incubated for 2–4 days inwere collected and purified by Ficoll-Plus (Amersham Pharmacia
RANK-L (60 ng/ml) and M-CSF (30 ng/ml).Biotech Inc., Arlington Height, IL). The cells were then incubated
For binding studies, RAW-C3 cells were washed with modifiedwith M-CSF (30 ng/ml) and RANK-L (60 ng/ml) for 4–6 days followed
Hanks’ solution and incubated in modified Hanks’ solution withby their staining for TRAP using a kit (Sigma) per manufacturer’s
125I-bTSH (10,000 cpm/well) and bovine TSH (106 mU/l) for 2 hr atinstruction. The number of TRAP-positive cells was counted. RAW-
37C in 96-well plates (Ando et al., 2002). Radioactivity of the cellC3 cells were cultured with RANK-L (10–100 ng/ml) for 3 days to form
lysate was measured after washing. As negative and positive con-
TRAP-positive osteoclasts. For osteoclast survival experiments, the
trols, CHO cells were transfected, respectively, with empty vector
cells were cultured with RANK-L (100 ng/ml) for 3 days and then
or human or murine TSHR (Ando et al., 2002).
with RANK-L (10 ng/ml) and rhTSH (10 U/l) for an additional 3 days.
For immunodetection of signaling molecules, namely Erk1/2, p38,
In separate experiments, a neutralizing polyclonal goat antimouse Akt, JNK, I
B, p65, p50, c-jun, and c-fos, Western immunoblotting
TNF antibody (R&D Systems Inc., Minneapolis, MN) was added was performed on whole-cell lysates and nuclear subfractions ob-
at 0.1 and 1.0 g/ml at day zero. Preimmune goat IgG was used tained as described previously (Shevde et al., 2000). The respective
as control. antibodies were obtained from Santa Cruz Biotechnology Inc. (Santa
For osteoblastogenesis experiments, bone marrow cells were cul- Cruz, CA) or Cell Signaling Technology, Inc. (Beverly, MA).
tured in the presence of ascorbic acid-2-phosphate (1 mM). At Bone marrow was collected from long bones dissected from
around 3 days, multicellular fibroblastoid colonies, CFU-Fs, ap- TSHR/ and TSHR/ mice and suspended in 1 ml -MEM. After
peared that became increasingly alkaline phosphatase positive over obtaining total cell counts, the suspension was centrifuged at 2000
the following week. CFU-F colonies were stained for alkaline phos- rpm for 5 min and the supernatant separated. ELISAs for TNF and
phatase using a kit per manufacturer’s recommendations (Sigma- IL-7 were performed on supernatants using capture and detection
Aldrich, St. Louis, MO). Upon further incubation, the colonies miner- antibodies for the two cytokines obtained from Pharmigen (San
alized to form CFU-osteoblast (CFU-OB) that stained brownish black Diego, CA) and R&D Systems Inc., respectively. The assay was
with von Kossa. CFU-F and CFU-OB numbers were determined (Abe established and optimized per manufacturer’s instruction.
et al., 2000; Sun et al., 2003).
For primary osteoblast cultures, calvaria from 4-day-old mice Real-Time PCR
were dissected and digested five times in sequence with collage- Total RNA was purified using RNeasy Mini kit (Qiagen, Valencia, CA)
nase (0.2% w/v) for 10 min each time. Fractions 2 to 5 were pooled per manufacturer’s protocol. Expression levels of various transcripts
and cultured for 3 days in -MEM for amplification, followed by were determined by quantitative real-time RT-PCR. Briefly, 5.0 g
differentiation in ascorbic acid-2-phosphate (1 mM). For explant total RNA was converted into cDNA using by Superscript II (In-
cultures, 1-day-old calvaria were maintained for 6 days in -MEM vitrogen, Carlsbad, CA) and 1/200 (500 pg) was utilized for 40
containing ascorbic acid-2-phosphate (1 mM). cycle two-step PCR in an ABI Prism 7000 (Applied Biosystems,
Foster City, CA) in SYBR Green Master Mix (ABI) and 200 nM primers.
Amplicon size and reaction specificity was confirmed by agaroseBone Phenotyping
gel electrophoresis. Each transcript in each sample was assayed 3BMD measurements were performed on anaesthetized mice using
times and the fold-change ratios between experimental and controla Lunar Piximus with an error of 1.5%. Whole-body BMD (with the
samples for each gene used in the analysis were calculated.cranium excluded) and region-specific measurements, notably of
the spine (L4–L6), right and left femur, and right and left tibia were
Acknowledgmentsmade. The instrument was calibrated each time before use by em-
ploying a phantom per manufacturer’s recommendation. In addition,
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